Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Rimmyrah 10 mg/ml solution for injection {equilateral_black_triangle}

{email} Notify me of changes to this product

emc account functionality

Sign in or register for an emc account to use this functionality and much more:

  • Get the latest updates to your inbox

    Receive email notifications when chosen products are updated

  • Stay up to date with document change history

    Get full access to document change history

  • Similar product search

    Use active ingredient, company or ATC code

  • Save your regular searches

    Simple access to search enquiries every time you need them

  • Favourite products you use most often

    Helps you find products you use regularly as fast as possible

Active Ingredient:
ranibizumab
Company:  
Orion Pharma (UK) Limited See contact details
ATC code: 
S01LA04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs Audio/Video
{arrow_left}
{arrow_right}
Rimmyrah nAMD educational materials - Audio Version
Audio version of Rimmyrah nAMD educational materials - Important safety information for patients treated with: RIMMYRAH (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD)

Rimmyrah CNV educational materials - Audio Version
Audio version of Rimmyrah CNV educational materials - Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV) secondary to pathological myopia

Rimmyrah PDR/DMO educational materials - Audio Version
Audio version of Rimmyrah DMO educational materials - Important safety information for patients treated with: RIMMYRAH (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO)

Rimmyrah RVO educational materials - Audio Version
Audio version of Rimmyrah RVO educational materials - Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to retinal vein occlusion (RVO)

Orion Pharma (UK) Limited
Company image
Address
9th Floor, The Blade, Abbey Square, Reading, RG1 3BE, UK
Telephone
+44 (0)1635 520 300
Medical Information e-mail
[email protected]
Out of Hours Telephone
+44 (0)1635 520 300
Adverse event reporting email
[email protected]
Stock Availability
orionukar&[email protected]
WWW
https://www.orionpharma.co.uk